CMS Expands Cervical Cancer Screening Coverage: What Billing Teams Need to Know About NCD 365
The Centers for Medicare & Medicaid Services (CMS) has issued a modification to National Coverage Determination (NCD) 365, governing screening for cervical cancer with Human Papillomavirus (HPV) testing. This update, effective March 12, 2026, clarifies and reaffirms CMS's coverage framework for HPV co-testing alongside Pap smears for eligible Medicare beneficiaries. If your practice bills cervical cancer screening services for Medicare patients, this policy directly affects how and when you can bill for HPV testing.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Screening for Cervical Cancer with Human Papillomavirus (HPV) |
| Policy Code | NCD 365 |
| Change Type | Modified |
| Effective Date | 2026-03-12 |
| Impact Level | Medium |
| Specialties Affected | OB/GYN, primary care, internal medicine, women's health, clinical laboratory |
| Key Action | Audit your HPV co-testing billing protocols to confirm patient age, screening interval, and conjunction-with-Pap-smear requirements are documented before claims go out. |
What CMS Covers Under NCD 365: HPV Testing and Cervical Cancer Screening
CMS covers two distinct but related cervical cancer screening benefits under Medicare, and it's critical for billing teams to understand where they intersect.
Pap smear and pelvic examination: Medicare has long covered screening pelvic examinations and Pap tests for all female beneficiaries. The interval is either every 12 months or every 24 months, depending on the patient's documented risk factors. This coverage is governed by 42 C.F.R. § 410.56 and NCD § 210.2.1.
HPV testing (co-testing): Effective for services performed on or after July 9, 2015, CMS determined sufficient evidence exists to cover HPV testing as an additional preventive service under §1861(ddd) of the Social Security Act. Coverage applies once every five years for asymptomatic beneficiaries aged 30 to 65, and only when performed in conjunction with a Pap smear.
The five-year interval for HPV co-testing is a firm coverage requirement, not a guideline. Claims submitted outside that window for routine screening will face denial.
Coverage Criteria: Who Qualifies for Medicare-Covered HPV Screening
Not every Medicare patient presenting for a Pap smear is eligible for covered HPV co-testing. The policy is specific, and documentation must reflect all of the following at the time of service:
| # | Covered Indication |
|---|---|
| 1 | Age: The beneficiary must be between 30 and 65 years old |
| 2 | Symptom status: The beneficiary must be asymptomatic — this is a screening benefit, not a diagnostic one |
| 3 | Conjunction requirement: HPV testing must be performed alongside a Pap smear, not as a standalone test |
| 4 | Frequency limit: No more than once every five years under this benefit |
If a patient presents with symptoms — abnormal discharge, irregular bleeding, or other clinical indicators — the encounter shifts from preventive screening to a diagnostic workup. That changes the benefit category, the applicable codes, and the documentation requirements entirely. Billing a symptomatic patient under the screening benefit is a compliance risk.
Laboratory Requirements: FDA Approval and CLIA Compliance Are Non-Negotiable
CMS will only cover HPV testing performed with laboratory tests that are:
- FDA approved or cleared for this indication
- Used consistent with FDA-approved labeling
- In compliance with Clinical Laboratory Improvement Act (CLIA) regulations
This is a meaningful requirement for practices that perform in-house laboratory work or use reference labs. If your lab partner is running an HPV assay that isn't FDA-cleared for cervical cancer screening co-testing, or if it's being used off-label, the claim is not covered under this NCD regardless of patient eligibility. Practices should confirm their laboratory's compliance status in writing and keep that documentation on file.
What Is Not Covered Under NCD 365
CMS draws a clear line in this policy: unless a preventive service is specifically covered by an NCD, a statute, or a regulation, it is non-covered under Medicare. There is no implied coverage for related services.
Specifically, standalone HPV testing — performed without a concurrent Pap smear — does not fall within this NCD's covered indications. Similarly, HPV testing for beneficiaries under 30 or over 65 is not covered under this benefit, even if clinically indicated for other reasons. Those situations may have separate diagnostic pathways, but they should not be billed under NCD 365 coverage parameters.
Practices that routinely perform HPV testing for patients outside the 30–65 age band or without a concurrent Pap should have a clear internal policy on how those claims are coded and whether advance beneficiary notice (ABN) requirements apply.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
The policy document for NCD 365 (Policy Key: 365-v1) does not list specific CPT or HCPCS codes within the coverage data provided. Billing teams should reference the associated Claims Processing Instructions — Transmittal 3460 (Medicare Claims Processing) — for the applicable procedure codes used when billing HPV co-testing under this NCD.
Work with your coding team or refer directly to CMS's Medicare Claims Processing Manual to confirm the current codes in use for:
- Screening Pap smear collection
- Pap smear laboratory interpretation
- HPV DNA detection testing (co-testing)
Because no codes are enumerated in the NCD itself, any code selection must be validated against CMS transmittal guidance and your MAC's local billing requirements.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Pull a frequency check on HPV co-testing claims before March 12, 2026. Run a report on all patients who received Medicare-covered HPV co-testing in the past five years. Flag any patients approaching or within the coverage window so front-desk staff can counsel appropriately before the next screening visit. |
| 2 | Update your eligibility and intake screening questions. Confirm that your intake workflow captures whether the patient is asymptomatic and documents the clinical context as preventive vs. diagnostic. A symptomatic patient billed under a screening benefit is an audit liability. |
| 3 | Verify your laboratory's FDA clearance and CLIA compliance status. Contact your reference lab or in-house lab director and request written confirmation that the HPV assay in use is FDA-approved for cervical cancer co-testing and that the facility is CLIA-compliant. Keep this documentation in your compliance file. |
| 4 | Review your ABN process for out-of-range patients. Establish a clear protocol for patients under 30 or over 65 who request or clinically need HPV testing. If Medicare won't cover the service under this NCD, an ABN must be issued before the service is rendered. |
| 5 | Cross-reference Transmittal 3460 for current billing codes. Since NCD 365 does not enumerate specific procedure codes, your coding team should pull the most current version of CMS Transmittal 3460 to confirm the correct codes to use and document that review. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.